A UK Biobank study suggests that higher intake of free sugars is associated with a higher risk to develop cardiovascular disease, UK researchers report in BMC Medicine.
https://european-biotechnology.com/wp-content/uploads/2024/04/Expansion_of_the_Munich.png540960Thomas Gabrielczyk/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngThomas Gabrielczyk2023-02-15 10:42:062024-06-21 14:05:29Expansion of the Munich science line has started
Fermatation expert Evonik SE has entered into an agreement with the German recombinant silk producer AMSilk to produce industrial quantities of innovative, sustainable silk proteins.
https://european-biotechnology.com/wp-content/uploads/2024/04/Bildschirmfoto_2023-02-14_um_17.00.23.png459971Thomas Gabrielczyk/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngThomas Gabrielczyk2023-02-15 06:01:002024-07-15 12:38:25AMsilk scaling up through Evonik collaboration
Cambridge-based endovascular surgical AI specialist Cydar Medical has completed a €10.5m (£9.3m) Series A funding round led by Pembroke Venture Capital Trust
https://european-biotechnology.com/wp-content/uploads/2024/04/Bildschirmfoto_2023-02-13_um_09.42.45.png366713Thomas Gabrielczyk/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngThomas Gabrielczyk2023-02-13 09:24:042024-04-04 16:44:47Cydar Medical Ltd raises €10.5m in Series A financing
British Evonetix Ltd has added US$$24m to its existing US$30m Series B financing round. The new financing was led by existing investor Foresite Capital.
https://european-biotechnology.com/wp-content/uploads/2024/04/evonteix-home-silicon-array.jpeg571800Thomas Gabrielczyk/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngThomas Gabrielczyk2023-02-07 17:13:432024-07-15 12:58:38Evonetix extends Series B financing to US$54m
Toulouse White Biotech (TWB) is a good example to how scaling and collaboration through production partnerships can help the industrial biotech sector to satisfy the urgent need to speed up and scale sustainable processes for industrial production.
https://european-biotechnology.com/wp-content/uploads/2024/04/Christian_Bo__hm.jpg16001600Thomas Gabrielczyk/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngThomas Gabrielczyk2023-02-07 11:46:002024-04-02 16:19:47TWB, an original model supporting the bioeconomy
https://european-biotechnology.com/wp-content/uploads/2024/04/Vetter_Supporting_efficient_drug_development_with_dedicated_clinical_development_expertise_Vial_Filling1-scaled.jpg18542560Thomas Gabrielczyk/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngThomas Gabrielczyk2023-02-06 16:32:392024-04-02 15:34:24Vetters Clinical Facility Demonstrates Success with Five Client Products Now on the Market
Free sugar linked to higher cardiovascular disease
Latest NewsA UK Biobank study suggests that higher intake of free sugars is associated with a higher risk to develop cardiovascular disease, UK researchers report in BMC Medicine.
Expansion of the Munich science line has started
BackgroundThe extension, which was celebrated with an official groundbreaking ceremony, will connect the IZB campus in Martinsried to the Munich subway system.
AMsilk scaling up through Evonik collaboration
Latest NewsFermatation expert Evonik SE has entered into an agreement with the German recombinant silk producer AMSilk to produce industrial quantities of innovative, sustainable silk proteins.
HOOKIPA bags US$10m cancer milestone
Latest NewsHOOKIPA has received a US$10m milestone under its 2022 agreement with Roche to develop an arenaviral immunotherapy for KRAS-mutated cancers.
Cydar Medical Ltd raises €10.5m in Series A financing
Latest NewsCambridge-based endovascular surgical AI specialist Cydar Medical has completed a €10.5m (£9.3m) Series A funding round led by Pembroke Venture Capital Trust
Upping sustainability in pharma packaging
Latest NewsHow to make pharma packaging sustainable was one of the major discussion topics at PHARMAPACK 2023.
Evonetix extends Series B financing to US$54m
Latest NewsBritish Evonetix Ltd has added US$$24m to its existing US$30m Series B financing round. The new financing was led by existing investor Foresite Capital.
TWB, an original model supporting the bioeconomy
BackgroundToulouse White Biotech (TWB) is a good example to how scaling and collaboration through production partnerships can help the industrial biotech sector to satisfy the urgent need to speed up and scale sustainable processes for industrial production.
Germanys Curevac offers common shares
Latest NewsmRNA vaccine pioneer CureVac N.V. has announced that it will sell US$200m of its common shares in an underwritten public offering.
Vetters Clinical Facility Demonstrates Success with Five Client Products Now on the Market
Sponsored PublicationsBoth the US Skokie and European Rankweil sites address customer needs in early-phase drug development